Mr. Reginald (Reg) Dupre has led EPIEN Medical since 1999 and steered the company through its start-up and technology development stages.  During the past five years, Reg has led the company through its commercialization stage and today the company’s products are sold in more than 40 countries.  Under his leadership, the company’s vision to develop and implement a state-of-the-art nonbiologic technology platform has become a reality.  This novel technology platform transcends dental, acute and chronic wound, surgical, dermatological, veterinary and other medical specialties that provide relief for patients suffering from debilitating infectious diseases.  He has also guided EPIEN’s marketing efforts to expand brand recognition of its oral healthcare products ORALMEDIC®, HYBENX® and soon REVITY™ at a global level.

As Chairman and CEO of EPIEN Medical, Reg has arranged capital from over 200 angel investors, banks and several large institutional investors to contribute to the company’s growth.  After 25 years in the medical business, he has led the company through US and European regulatory clearances, built international patent portfolios, completed over 25 clinical trials and has negotiated distribution agreements with major distributors worldwide.

Prior to becoming CEO of EPIEN Medical, Reg held various board-elected leadership positions in several start-ups and mature companies that needed turnaround leadership expertise and/or new capital.  Some of these companies include Sustane Corporation, Rem-Con and the Minnesota Renaissance Festival.  Prior to these executive roles and capital raises, Reg had spent 14 years in a variety of business development, strategic marketing, and sales management roles at Honeywell and Control Data.

Following Reg’s undergraduate work at the University of Minnesota, he received a bachelor’s degree in business administration from the Metropolitan State University.  He continued his studies at the University of St. Thomas in International Marketing.